IP Library › Granted Patent US 12,377,170
Granted Patent B2
US 12,377,170 · App. 17/432,417 · Granted Aug 5, 2025

Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy

Inventors: Louise Rodino-Klapac (Columbus, OH); Jerry R. Mendell (Columbus, OH)
Assignee: Research Institute at Nationwide Children's Hospital
A61K48/0075A61K38/1719A61K48/0041A61K48/0083A61P21/00C12N15/86C12N2750/14042C12N2750/14071
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,170
App. No.
17/432,417
Granted
Aug 5, 2025
Kind
B2
Abstract

Described herein are methods of treating muscular dystrophy comprising administering a recombinant AAV (rAAV) scAAVrh74.MHCK7.hSGCB vector, methods of expressing beta-sarcoglycan gene in a patient, pharmaceutical compositions comprising the rAAV, and methods of generating the rAAV. The disclosed methods reduce fibrosis and improve muscle function by restoring B-sarcoglycan expression in muscle tissues. The disclosure further provides preclinical studies in animal models, and a clinical trial involving systemic delivery of the vector to patients, which shows significant improvements in muscle pathology, force production, and overall activity in treated subjects.

Claims (18)

1. A method of treating limb-girdle muscular dystrophy Type 2E (“LGMD2E”) in a subject in need thereof, comprising the step of administering a recombinant adeno-associated virus (rAAV) which comprises SEQ ID NO: 19 to the subject, wherein

the rAAV is administered using a systemic route of administration and at a dose of a) about 1.85×10 13 vg/kg or about 7.41×10 13 vg/kg based on a linearized plasmid as the quantitation standard, or b) about 1.0×10 13 vg/kg or about 5.0×10 14 vg/kg based on a supercoiled plasmid as the quantitation standard.

2. A method of treating limb-girdle muscular dystrophy Type 2E (“LGMD2E”) in a subject in need thereof, comprising the step of administering a recombinant adeno-associated virus (rAAV) which comprises SEQ ID NO: 19 to the subject,

wherein administration of the rAAV decreases the serum creatine kinase (CK) level in the subject as compared to the serum CK level before the administration of the rAAV.

3. The method of claim 1 , wherein the rAAV is administered using an intravenous route.

4. The method of claim 2 , wherein the rAAV is administered at about 1.0×10 13 vg/kg or about 5.0×10 14 vg/kg based on a supercoiled plasmid as the quantitation standard, or about 1.85×10 13 vg/kg or 7.41×10 13 vg/kg based on a linearized plasmid as the quantitation standard.

5. The method of claim 1 , wherein the rAAV comprises one or more of the following:

(i) nucleotide sequence of SEQ ID NO: 1,

(ii) the MHCK7 promoter sequence of SEQ ID NO: 4,

(iii) an intron sequence of SEQ ID NO: 20,

(iv) a polyA sequence of SEQ ID NO: 21,

(v) 5′ inverted terminal repeat (ITR) sequence of SEQ ID NO: 22, and

(vi) 3′ inverted terminal repeat (ITR) sequence of SEQ ID NO: 23.

6. The method of claim 1 , wherein the rAAV is administered at a dose of about 1.0×10 13 vg/kg to about 1.0×10 14 vg/kg based on a supercoiled plasmid as the quantitation standard.

7. A method of treating limb-girdle muscular dystrophy Type 2E in a subject in need, comprising administering to the subject an intravenous infusion of an rAAV construct over approximately 1 to 2 hours at a dose of about 5.0×10 13 vg/kg or about 2.0×10 14 vg/kg based on a supercoiled plasmid as the quantitation standard, or about 1.85×10 13 vg/kg or 7.41×10 13 vg/kg based on a linearized plasmid as the quantitation standard, and wherein the rAAV construct comprises SEQ ID NO: 19.

8. The method of claim 1 , wherein the subject is a human subject that is (i) 4 to 15 years of age, (ii) 25 to 55 years of age, or (iii) over 50 years of age.

9. The method of claim 1 , wherein the rAAV is administered using a systemic route of administration and at a dose of 7.41×10 13 vg/kg based on a linearized plasmid as the quantitation standard.

10. A method of increasing localization of alpha-sarcoglycan to a cell membrane in a subject in need thereof comprising administering to the subject a recombinant adeno-associated virus (rAAV) construct which comprises SEQ ID NO: 19.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2021
From: RODINO-KLAPAC, LOUISE; MENDELL, JERRY R
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 057269/0240 →
Continuity (7)
Provisional Application 62910779 · Oct 4, 2019
Provisional Application 62909564 · Oct 2, 2019
Provisional Application 62881901 · Aug 1, 2019
Provisional Application 62858644 · Jun 7, 2019
Provisional Application 62834012 · Apr 15, 2019
Provisional Application 62810917 · Feb 26, 2019
Related Publication 20230241252A1 · Aug 3, 2023
References Cited (400)
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5449616A · Campbell et al. · 1995 [cited by applicant]
US 5658776A · Flotte et al. · 1997 [cited by applicant]
US 5672694A · Campbell et al. · 1997 [cited by applicant]
US 5786211A · Johnson · 1998 [cited by applicant]
US 5871982A · Wilson et al. · 1999 [cited by applicant]
US 6008036A · Fanget et al. · 1999 [cited by applicant]
US 6204059B1 · Samulski et al. · 2001 [cited by applicant]
US 6258595B1 · Gao et al. · 2001 [cited by applicant]
US 6262035B1 · Campbell et al. · 2001 [cited by applicant]
US 6566118B1 · Atkinson et al. · 2003 [cited by applicant]
US 6632800B1 · Russell et al. · 2003 [cited by applicant]
US 7282199B2 · Gao et al. · 2007 [cited by applicant]
US 7759314B2 · Fallon et al. · 2010 [cited by applicant]
US 7790449B2 · Gao et al. · 2010 [cited by applicant]
US 7883858B2 · Hood et al. · 2011 [cited by applicant]
US 9061059B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9434928B2 · Mendell et al. · 2016 [cited by applicant]
US 10105453B2 · Mendell et al. · 2018 [cited by applicant]
US 11358993B2 · Rodino-Klapac et al. · 2022 [cited by applicant]
US 20010029040A1 · Toyo-Oka · 2001 [cited by applicant]
US 20030225260A1 · Snyder · 2003 [cited by applicant]
US 20060154250A1 · Morris et al. · 2006 [cited by applicant]
US 20070099251A1 · Zhang et al. · 2007 [cited by applicant]
US 20080249052A1 · Duan et al. · 2008 [cited by applicant]
US 20090054823A1 · Bridges et al. · 2009 [cited by applicant]
US 20090275107A1 · Lock et al. · 2009 [cited by applicant]
US 20090280103A1 · Flueck · 2009 [cited by applicant]
US 20100003218A1 · Duan et al. · 2010 [cited by applicant]
US 20100008979A1 · Tomatsu et al. · 2010 [cited by applicant]
US 20100026655A1 · Harley · 2010 [cited by applicant]
US 20100075866A1 · Hood et al. · 2010 [cited by applicant]
US 20100112694A1 · Marban · 2010 [cited by applicant]
US 20100120627A1 · Belouchi et al. · 2010 [cited by applicant]
US 20100247495A1 · Ichim et al. · 2010 [cited by applicant]
US 20100266551A1 · Richard et al. · 2010 [cited by applicant]
US 20110023139A1 · Weinstein et al. · 2011 [cited by applicant]
US 20110053221A1 · Chen et al. · 2011 [cited by applicant]
US 20110070210A1 · Andrijauskas · 2011 [cited by applicant]
US 20110076744A1 · Wright et al. · 2011 [cited by applicant]
US 20110082192A1 · Milne et al. · 2011 [cited by applicant]
US 20110104120A1 · Xiao et al. · 2011 [cited by applicant]
US 20110266551A1 · Thompson et al. · 2011 [cited by applicant]
US 20110294193A1 · Amalfitano et al. · 2011 [cited by applicant]
US 20110301226A1 · Mendell et al. · 2011 [cited by applicant]
US 20120087862A1 · Hood et al. · 2012 [cited by applicant]
US 20130171172A1 · Richard et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147432A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140179770A1 · Zhang et al. · 2014 [cited by applicant]
US 20140234255A1 · Lai et al. · 2014 [cited by applicant]
US 20140249208A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140256802A1 · Boye et al. · 2014 [cited by applicant]
US 20140273231A1 · Zhang et al. · 2014 [cited by applicant]
US 20140323956A1 · Mendell et al. · 2014 [cited by applicant]
US 20150111955A1 · High et al. · 2015 [cited by applicant]
US 20150125429A1 · Perlingeiro et al. · 2015 [cited by applicant]
US 20150232883A1 · Dahlman et al. · 2015 [cited by applicant]
US 20150238627A1 · Leger et al. · 2015 [cited by applicant]
US 20160058890A1 · Buj Bello et al. · 2016 [cited by applicant]
US 20180256752A1 · Buj Bello et al. · 2018 [cited by applicant]
US 20190000998A1 · Mendell et al. · 2019 [cited by applicant]
US 20190202880A1 · Rodino-Klapac et al. · 2019 [cited by applicant]
US 20200339960A1 · Sahenk · 2020 [cited by applicant]
US 20210128749A1 · Rodino-Klapac et al. · 2021 [cited by applicant]
US 20210393801A1 · Rodino-Klapac et al. · 2021 [cited by applicant]
US 20230390417A1 · Sahenk · 2023 [cited by applicant]
CN 101896186A · 2010 [cited by applicant]
CO 20210000227A2 · 2021 [cited by applicant]
EP 0127839A2 · 1984 [cited by applicant]
EP 0155476A · 1985 [cited by applicant]
EP 2170325A · 2010 [cited by applicant]
EP 2859896A1 · 2015 [cited by applicant]
EP 3030666A · 2016 [cited by applicant]
JP 2006121961A · 2006 [cited by applicant]
JP 2015509711A · 2015 [cited by applicant]
JP 2016515831A · 2016 [cited by applicant]
WO 9503392A1 · 1995 [cited by applicant]
WO 9513365A1 · 1995 [cited by applicant]
WO 9513392A1 · 1995 [cited by applicant]
WO 9617947A1 · 1996 [cited by applicant]
WO 9706243A1 · 1997 [cited by applicant]
WO 9708298A1 · 1997 [cited by applicant]
WO 9709441A2 · 1997 [cited by applicant]
WO 9721825A1 · 1997 [cited by applicant]
WO 9809657A2 · 1998 [cited by applicant]
WO 9901176A1 · 1999 [cited by applicant]
WO 9911764A2 · 1999 [cited by applicant]
WO WO9943360A1 · 1999 [cited by applicant]
WO 0183692A2 · 2001 [cited by applicant]
WO 0253703A2 · 2002 [cited by applicant]
WO WO03074714A1 · 2003 [cited by applicant]
WO 2004058146A2 · 2004 [cited by applicant]
WO WO2007057781A2 · 2007 [cited by applicant]
WO WO2009019505A2 · 2009 [cited by applicant]
WO 2009054725A2 · 2009 [cited by applicant]
WO 2013016352A1 · 2013 [cited by applicant]
WO 2013078316A1 · 2013 [cited by applicant]
WO WO2013123503A1 · 2013 [cited by applicant]
WO WO2013151665A2 · 2013 [cited by applicant]
WO WO2013176772A1 · 2013 [cited by applicant]
WO WO2014037526A1 · 2014 [cited by applicant]
WO WO2014039916A1 · 2014 [cited by applicant]
WO WO2014093622A2 · 2014 [cited by applicant]
WO WO2014093701A1 · 2014 [cited by applicant]
WO WO2014093712A1 · 2014 [cited by applicant]
WO WO2014204725A1 · 2014 [cited by applicant]
WO WO2015018503A1 · 2015 [cited by applicant]
WO WO2015021457A2 · 2015 [cited by applicant]
WO 2015110449A1 · 2015 [cited by applicant]
WO WO2015158749A2 · 2015 [cited by applicant]
WO 2015197232A1 · 2015 [cited by applicant]
WO WO2016115543A2 · 2016 [cited by applicant]
WO WO2017087395A1 · 2017 [cited by applicant]
WO WO2017165859A1 · 2017 [cited by applicant]
WO 2017180857A1 · 2017 [cited by applicant]
WO 2017180976A1 · 2017 [cited by applicant]
WO WO2017181014A1 · 2017 [cited by applicant]
WO WO2017181015A1 · 2017 [cited by applicant]
WO WO2017221145A1 · 2017 [cited by applicant]
WO WO2018170408A1 · 2018 [cited by applicant]
WO WO2019012336A1 · 2019 [cited by applicant]
WO WO2019078916A1 · 2019 [cited by applicant]
WO WO2019118806A1 · 2019 [cited by applicant]
WO WO2019152474A1 · 2019 [cited by applicant]
WO WO2019195362A1 · 2019 [cited by applicant]
WO WO2019209777A1 · 2019 [cited by applicant]
WO WO2019245973A1 · 2019 [cited by applicant]
WO WO2020006458A1 · 2020 [cited by applicant]
WO WO2020123645A1 · 2020 [cited by applicant]
WO WO2021035120A1 · 2021 [cited by applicant]
WO WO2021257655A1 · 2021 [cited by applicant]
Monies, Dorota, et al. “A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies.” Human Genomics 10 (2016): 1-7. (Year: 2016). [cited by examiner]
Theadom, Alice, et al. “Prevalence of muscular dystrophies: a systematic literature review.” Neuroepidemiology 43.3-4 (2015): 259-268. (Year: 2015). [cited by examiner]
Chu, Mary Lynn, and Ellen Moran. “The limb-girdle muscular dystrophies: is treatment on the horizon?.” Neurotherapeutics 15.4 (2018): 849-862. (Year: 2018). [cited by examiner]
Walter, Maggie C., and Peter Reilich. “Recent developments in Duchenne muscular dystrophy: facts and numbers.” Journal of cachexia, sarcopenia and muscle 8.5 (2017): 681. (Year: 2017). [cited by examiner]
Moore, Steven A., et al. “Limb-girdle muscular dystrophy in the United States.” Journal of Neuropathology & Experimental Neurology 65.10 (2006): 995-1003. (Year: 2006). [cited by examiner]
Wagner, Anke, et al. “A novel method for the quantification of adeno-associated virus vectors for RNA interference applications using quantitative polymerase chain reaction and purified genomic adeno-associated virus DN… [cited by examiner]
McCarty, D. M. (2008). Self-complementary AAV vectors; advances and applications. Molecular therapy, 16(10), 1648-1656. (Year: 2008). [cited by examiner]
Cordier et al., “Muscle-Specific Promoters May Be Necessary for Adeno-Associated Virus-Mediated Gene Transfer in the Treatment of Muscular Dystrophies,” Human Gene Therapy, Jan. 20, 2001, vol. 12, pp. 205-215. [cited by applicant]
Cordier et al., “Rescue of Skeletal Muscles of gamma-Sarcoglycan-Deficient Mice with Adeno-Associated Virus-Mediated Gene Transfer,” Molecular Therapy, Feb. 2000, vol. 1, No. 2 pp. 119-129. [cited by applicant]
Herson et al., A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular type 2C, Brain, 2012, vol. 135, Pt 2, pp. 483-492. [cited by applicant]
McNally et al., “Mild and Severe Muscular Dystrophy Caused by a Single gamma-Sarcoglycan Mutation”, American Journal of Human Genetics, Nov. 1996, vol. 59, No. 5, pp. 1040-1047. [cited by applicant]
NCBI, GenBank accession No. U34976.1 (Nov. 8, 1995), 2 pages. [cited by applicant]
Noguchi S, “Human gamma-sarcoglycan mRNA, complete cds.”, NCBI, (Nov. 8, 1995), Database accession No. U34976, 2 pages. [cited by applicant]
Pozsgai et al., “506. [beta]—Sarcoglycan Gene Transfer Prevents Muscle Fibrosis and Inflammation in an Aged LGMD2E Mouse Model,” Molecular Therapy, vol. 23 Supplement 1, May 2015, 2 pages. [cited by applicant]
Rose, comprehensive Virology 3:1-61 (1974). [cited by applicant]
Dorange et al., “Analytical approaches to characterize AAV vector production & purification: Advances and challenges,” Cell & Gene Therapy Insights, 4(2):119-129 (2018). [cited by applicant]
Hou et al., “Serious Overestimation in Quantitative PCR by Circular (Supercoiled) Plasmid Standard: Microalgal pcna as the Model Gene,” PLoS One 5(3):e9545, 8 pages (Mar. 5, 2010) doi:10.1371/journal.pone.0009545. [cited by applicant]
Martinez-Fernandez de la Camara et al., “The accurate quantification of AAV genomic titre depends on the conformation of the plasmid reference,” ARVO Annual Meeting Abstract, 3 pages, Jul. 2018. [cited by applicant]
Wu et al., “Adeno-associated virus serotypes: vector toolkit for human gene therapy.” Molecular therapy 14.3 (2006): 316-327 (Year: 2006). [cited by applicant]
Anderson et al., Nucleic Acid Hybridisation: A Practical Approach, IRL Press Limited, Oxford, England, Ch. 4 (1985). [cited by applicant]
Angelini et al., The clinical spectrum of sarcoglycanopathies. Neurology. 52:176-179 (1999). [cited by applicant]
Araishi et al., Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in beta-sarcoglycan-deficient mice, Hum. Mol. Genet. 8: 1589-1598 (1999). [cited by applicant]
Barresi et al., Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations, J. Med. Genet. 37: 102-107 (2000). [cited by applicant]
Beastrom et al., mdx(5cv) mice manifest more severe muscle dysfunction and diaphragm force deficits than do mdx Mice, Am. J. Pathol., 179(5):2464-74 (2011). [cited by applicant]
Bonnemann et al., Betasarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex, Nat. Genet., 11(3):266-273 (1995). [cited by applicant]
Bonnemann et al., Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E), Hum. Mol. Genet. 5:1953-1961 (1996). [cited by applicant]
Chao et al., Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors, Mol. Ther., 2(6):619-623 (2000). [cited by applicant]
Chao et al., Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors, Mol. Ther., 4(3):217-222 (2001). [cited by applicant]
Chicoine et al., Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery, Mol. Ther., 22(2):338-347 (2014). [cited by applicant]
Chicoine et al., Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin a2 surrogates. Mol. Ther. 22:713-724 (2014). [cited by applicant]
Chu et al., SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen, Gene., 13(2):197-202 (1981). [cited by applicant]
Clark et al., Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum. Gene Ther. 10:1031-1039 (1999). [cited by applicant]
Clark et al., Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle, Hum. Gene. Ther., 8(6):659-669 (1997). [cited by applicant]
Clark et at., A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors, Gene. Ther. 3:1124-32 (1996). [cited by applicant]
Cserjesi et al., Myogenin induces the myocyte-specific enhancer binding factor MEF-2 independently of other muscle-specific gene products, Mol. Cell. Biol., 11(10):4854-4862 (1991). [cited by applicant]
De et al., High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, Mol. Th… [cited by applicant]
Draviam et al., The -li-core of sarcoglycan is essential for deposition at the plasma membrane, Muscle and Nerve. 34:691-701 (2006). [cited by applicant]
Dressman et al., Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity, Hum. Gene. Ther., 13(13):1631-1646 (2002). [cited by applicant]
Dressman, D., AAV-Mediated gene transfer to models of muscular dystrophy: Insights into assembly of multi-subunit membrane proteins, University of Pittsburgh (1997). [cited by applicant]
Durbeej et al., Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E, Mol. Cell. 5:141-151 (2000). [cited by applicant]
Fanin et al., LGMD2E patients risk developing dilated cardiomyopathy, Neuromuscl. Disord., 13(4):303-309 (2003). [cited by applicant]
Flotte et al., Gene expression from adeno-associated virus vectors in airway epithelial cells, Am. J. Respir Mol. Biol. 7:349-356. 1992. [cited by applicant]
Gao et al., Clades of Adeno-associated Viruses are Widely Disseminated in Human Tissues, J. Virol., 78:6381-6388 (2004). [cited by applicant]
GenBank Accession No. AF085716.1, Adena-associated virus 5 DNA binding trs helicase (Rep22) and capsid protein (VP1) aenes, complete eds, Feb. 9, 1999. [cited by applicant]
GenBank Accession No. AX753246.1, Sequence 1 from Patent EP1310571, Jun. 23, 2003. [cited by applicant]
GenBank Accession No. AX753249.1, Sequence 4 from Patent EP1310571, Jun. 23, 2003. [cited by applicant]
Genbank Accession No. NC_001401.0, Adena-associated virus—2, complete genome, Aug. 13, 2018. [cited by applicant]
Genbank Accession No. NC_001729.1, Adena-associated virus—3, complete genome, Aug. 13, 2018. [cited by applicant]
GenBank Accession No. NC_001829.1, Adena-associated virus—4, complete genome, Aug. 13, 2018. [cited by applicant]
GenBank Accession No. NC_001862, Adena-associated virus 6, complete genome, Jan. 12, 2004. [cited by applicant]
Genbank Accession No. NC_002077.1, Adena-associated virus—1, complete genome, Aug. 13, 2018. [cited by applicant]
Genbank Accession No. NM_00232.4, [cited by applicant]
Genbank Accession No. NP_000233.1, Beta Sarcoglyan (43kD dystrophin-associated glycoprotein) [cited by applicant]
GenBank: Accession No. NP_000223.1: beta-sarcoglycan sequence, dated Mar. 3, 1999. [cited by applicant]
Gibertini et al., Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse, Cell Tissue Res. 356:427-443 (2014). [cited by applicant]
Graham et al., A new technique for the assay of infectivity of human adenovirus 5 DNA, Virology, 52(2):456-67 (1973). [cited by applicant]
Greig et al., Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques, Mol. Ther. Methods Clin. Dev., 3(C):16079 (2016). [cited by applicant]
Grieger et al., Production and characterization of adeno-associated viral vectors, Nat. Protoc. 1:1412-1428 (2006). [cited by applicant]
Hakim et al., The passive mechanical properties of the extensor digitorum longus muscle are compromised in 2- to 20-mo-old mdx mice, J. Appl. Physiol. 110: 1656-1663 (2011). [cited by applicant]
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells, Proc. Natl. Acad. Sci. USA. 81:6466-70 (1984). [cited by applicant]
Herzog et al., Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA, 94(11):5804-5809 (1997). [cited by applicant]
International Application No. PCT/US2017/027583, International Preliminary Report on Patentability, mailed Oct. 25, 2018. [cited by applicant]
International Application No. PCT/US2017/027583, International Search Report and Written Opinion, mailed Jul. 14, 2017. [cited by applicant]
International Application No. PCT/US2020/019892, International Preliminary Report on Patentability, mailed Sep. 10, 2021. [cited by applicant]
International Application No. PCT/US2020/019892, International Search Report and Written Opinion, mailed May 14, 2020. [cited by applicant]
International Preliminary Report on Patentability, PCT/US2017/027636 (Oct. 16, 2018). [cited by applicant]
International Search Report and Written Opinion, PCT/US2017/027636 (Jul. 5, 2017). [cited by applicant]
Johnson et al., Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice, Mol. Cell. Biol., 9(8):3393-3399 (1989). [cited by applicant]
Kessler et al., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Nat. Acad. Sci. USA, 93(24):14082-14087 (1996). [cited by applicant]
Straub et al., Animal models for muscular dystrophy show different patterns of sarcolemmal disruption, J. Cell Biol. 139:375-385 (1997). [cited by applicant]
Sun et al., Correction of Multiple Striated Muscles in Murine Pompe Disease Through Adena-Associated Virus-mediated Gene Therapy, Mol. Ther., 16(8):1366-71 (2008). [cited by applicant]
Sveen et al., Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy, Arch. Neurol., 65(9):1196-1201 (2008). [cited by applicant]
Tratschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase, Mol. Cell. Biol. 4:2072-81 (198… [cited by applicant]
Tratschin et al., Adena-associated virus vector for high-frequency integration, expression, and rescue of qenes in mammalian cells, Mol. Cell. Biol. 5:3251-60 (1985). [cited by applicant]
Voikar et al., Long-term individual housing in C57BL/6J and DBA/2 mice: assessment of behavioral consequences, Genes Brain Behav., 4(4):240-52 (2005). [cited by applicant]
Wang et al., Construction and analysis of compact muscle-specific promoters for AAV vectors, Gene Ther. 15:1489-1499 (2008). [cited by applicant]
Wang et al., Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis, Mol. Ther., 20(6):1222-33 (2012). [cited by applicant]
Wein et al., Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice, Nat. Med. 20: 992-1000 (2014). [cited by applicant]
Weintraub et al., The myoD gene family: nodal point during specification of the muscle cell lineage, Science. 251:761-766 (1991). [cited by applicant]
Wong-Kisiel et al., Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort, Neuromusc. Disord. 20:122-124 (2010). [cited by applicant]
Xiao et al., Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector, J. Virol., 70(11):8098-8108 (1996). [cited by applicant]
Xiao et al., Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus, J. Virol., 72:2224-2232 (1998). [cited by applicant]
Xu et al., An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque, Mol. Ther. Methods Clin. Dev., 10:89-104 (2018). [cited by applicant]
Zanotti et al., Opposing roles of miR-21 and miR-29 in the progression of fibrosis in Duchenne muscular dystrophy., Biochem. Biophys. Acta., 1852:1451-4 (2015). [cited by applicant]
Zhang et al., Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy, Hum. Mol. Genet. 22:3720-9 (2013). [cited by applicant]
Griffin et al. Preclinical systemic delivery of adeno-associated [alpha]-sarcoglycan gene transfer for limb-girdle mscular dystrophy, Human Gene Therapy, 32(7-8): 390-404, (Apr. 2021). [cited by applicant]
Inouye et al., Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons, Protein Expression and Purification, 109: 47-54, (May 2015). [cited by applicant]
Mendell et al., Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D, Annals of Neural. 68(5): 629-638, (Oct. 2010). [cited by applicant]
Raj Deepak et al., Self-complementary adeno-associated viral vectors for gene therapy of a hemophilia B: progress and challenges, Exert Review of Hemtol. England, Informa UK, 4(5): 539-549, (Nov. 2011). [cited by applicant]
Francois et al., Accurate titration of infectious AAV particles requires measurement of biologically active vector genomes and suitable controls, Mol. Ther., 10:223-236, (Sep. 2018). [cited by applicant]
Fowler, et al., Improved knockdown from artificial microRNAs in an enhanced miR-155 Backbone: a designer's guide to potent multi-target RNAi, Nucleic Acids Research, 44(5): e48, (Nov. 2015). [cited by applicant]
Kobayashi et al., Sarcolemma-localized nNOS is required to maintain activity after mild exercise, Nature. 456:511-5 (2008). [cited by applicant]
Kotin et al., Manufacturing Clinical Grade Recombinant Adena-Associated Virus Using Invertebrate Cell Lines, Hum. Gene Ther., 28(4):350-360 (2017). [cited by applicant]
Laughlin et al., Cloning of infectious adeno-associated virus genomes in bacterial plasmids, Gene. 23:65-73 (1983). [cited by applicant]
Laws et al., Progression of kyphosis in mdx mice, J. Appl. Physiol. 97:1970-7 (2004). [cited by applicant]
Lebkowski et al., Adena-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types, Mol. Cell. Biol. 8:3988-96 (1988). [cited by applicant]
Lewis et al., Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer, J. Virol., 76(17):8769-8775 (2002). [cited by applicant]
Liu et al., Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury, Mol. Ther., 11(2):245-256 (2005). [cited by applicant]
Mader et al., A steroid-inducible promoter for the controlled overexpression of cloned genes in eukaryotic cells, Proc. Natl. Acad. Sci. U.S.A., 90(12):5603-5607 (1993). [cited by applicant]
Marsic et al., Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants, Molecular Therapy, 22(11):1900-1909 (2014). [cited by applicant]
McCarty et al., Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo, Gene. Ther., 10(26):2112-2118 (2003). [cited by applicant]
McCarty et al., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene Ther. 8: 1248-1254 (2001). [cited by applicant]
McLaughlin et al., Adena-associated virus general transduction vectors: analysis of proviral structures, J. Virol. 62:1963-73 (1988). [cited by applicant]
Meadows et al., Micro-RNA-29 Overexpression by adeno-associated virus suppresses fibrosis in mdx:utrn+/− Mice (S61.003), Neurology. 82:S61.003 (Abstract) (2014). [cited by applicant]
Meadows et al., Reducing Skeletal Muscle Fibrosis with AAV-Delivered miR-29 (P04.089), Neural., 1 Supplement, (2012). [cited by applicant]
Melacini et al., Heart involvement in muscular dystrophies due to sarcoglycan gene mutations, Muscle Nerve. 22:473-479 (1999). [cited by applicant]
Mendell et al., A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy, Mol. Ther., 23: 192-201 (2015). [cited by applicant]
Mendell et al., Gene Therapy for Spinal Muscular Atrophy Type 1 Shows Potential to Improve Survival and Motor Functional Outcomes, Mol. Ther. 24:S190 (2016). [cited by applicant]
Mendell et al., Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy, N. Engl. J. Med., 377:1713-1722 (2017). [cited by applicant]
Merten, AAV vector production: state of the art developments and remaining challenges, Cell Gene Therapy Insights, 2(5):521-551 (2016). [cited by applicant]
Moore et al., Limb-girdle muscular dystrophy in the United States, J. Neuropathol. Exp. Neurol., 65(10):995-1003 (2006). [cited by applicant]
Moorwood et al., Isometric and eccentric force generation assessment of skeletal muscles isolated from murine models of muscular dystrophies, Journal of Visualized Experiments. 71:e50036 (2013). [cited by applicant]
Mori et al., Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein, Virology, 330(2):375-383 (2004). [cited by applicant]
Murphy et al., Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin, Proc. Natl. Acad. Sci. USA, 94(25):1… [cited by applicant]
Muscat et al., Multiple 5′-flanking regions of the human alpha-skeletal actin gene synergistically modulate muscle-specific expression, Mol. Cell. Biol., 7(11):4089-4099 (1987). [cited by applicant]
Muzyczka, Use of adeno-associated virus as a general transduction vector for mammalian cells, Curr. Top. Microbiol. Immunol. 158:97-129 (1992). [cited by applicant]
Narayanaswami et al., Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practi… [cited by applicant]
Paul et al., Increased viral titer through concentration of viral harvests from retroviral packaging lines, Hum. Gene. Ther. 4:609-15 (1993). [cited by applicant]
Perrin et al., An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system, Vaccine. 13:1244-50 (1995). [cited by applicant]
Pozsgai et al.,—Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice, Gene Ther. 23:57-66 (2016). [cited by applicant]
Pozsgai et al., 172. Pre-Clinical Efficacy Study of Beta-Sarcoglycan Gene Transfer, Malec. Ther., 21(1):s68 (2013). [cited by applicant]
Pozsgai et al., Beta-Sarcoglycan Gene Transfer Leads to Functional Improvement in a Model of LGMD2E (S61.002), Neur., 82(10):1-3 (2014). [cited by applicant]
Pozsgai et al., Systemic AAV-mediated (Beta)-sarcoglycan delivery targeting cardiac and Skeletal muscle ameliorates histological and functional deficits in LGMD2E mice, Mol. Ther. 25(4):855-869 (2017). [cited by applicant]
Rabinowitz et al., Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol. 76:791-801 (2002). [cited by applicant]
Rafael-Fortney et al., Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in duchenne muscular dystrophy mice, Circulation. 124:582-8 (2011). [cited by applicant]
Rodino-Klapac et al., A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy, J. Transl. Med. 5:45 (2007). [cited by applicant]
Rodino-Klapac et al., Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D, Neurology. 71: 240-247 (2008). [cited by applicant]
Rodino-Klapac et al., Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery, Mol. Ther. 18:109-117 (2010). [cited by applicant]
Ruffing et al., Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif Free, J. Gen. Virol., 75:3385-3392 (1994). [cited by applicant]
Salva et al., Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther., 15(2):320-9 (2007). [cited by applicant]
Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (2nd ed. 1989). [cited by applicant]
Samulski et al., Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells, Proc. Natl. Acad. Sci. USA. 79:2077-81 (1982). [cited by applicant]
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression, J. Virol. 63:3822-8 (1989). [cited by applicant]
Sandona et al., Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects, Exp Rev. Mol. Med. 11:e28 (2009). [cited by applicant]
Schnepp et al., Highly purified recombinant adeno-associated virus vectors. Preparation and quantitation, Methods Mol. Med. 69:427-43 (2002). [cited by applicant]
Semenza et al., Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene, Proc. Natl. Acad. Sci. U.S.A., 88(13):5680-5684 (1991). [cited by applicant]
Semplicini et al., Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E, Neurology. 84:1772-81 (2015). [cited by applicant]
Senapathy et al., Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells, J. Biol. Chem. 259:4661-6 (1984). [cited by applicant]
Shield et al., E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice, Mol. Cell. Biol., 16(9… [cited by applicant]
Srivastava et al., Nucleotide sequence and organization of the adeno-associated virus 2 genome, J. Virol. 45:555-64 (1983). [cited by applicant]
Abadi et al., Supplementation with alpha-lipoic acid, CoQ10, and vitamin E augments running performance and mitochondrial function in female mice, PLoS One, 8(4):e60722 (2013). [cited by applicant]
ABSS (Sequence Alignment; WO2020006458, SEQ ID #1; accessed Mar. 12, 2024) (Year: 2024). [cited by applicant]
ABSS2 (Sequence Alignment; U.S. Appl. No. 17/255,488, SEQ ID #1; accessed Mar. 12, 2024) (Year: 2024). [cited by applicant]
Allamand et al., Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice, Gene Ther., 7(16):1385-91 (2000). [cited by applicant]
Anderson et al., “Quantitative Filter Hybridisation—Chapter 4”, Nucleic acid hyridisation a practical approach, 1985, pp. 73-111. [cited by applicant]
Arnold et al., Electrophysiological Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept, Ann. Clin. Transl. Neural., 1 (1 ):34-44 (Jan. 2014). [cited by applicant]
Asokan et al., The AAV Vector Toolkit: Poised at the Clinical Crossroads; Molecular Therapy, 20(4):699-708 (2012). [cited by applicant]
Au et al., “Gene therapy advances: a meta-analysis of AAV Usage in Clinical Settings,” Frontiers in Medicine, Feb. 9, 2022, vol. 8 (pp. 1-14). [cited by applicant]
Bang et al., The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system, Gire. Res. 89:1065-72 (… [cited by applicant]
Bartoli et al., “Safety and efficacy of AA V-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A”, Mol. Ther., 13(2):250-259 (2006). [cited by applicant]
Bearzi et al., Human cardiac stem cells, Proc. Natl. Acad. Sci. USA. 104:14068-73 (2007). [cited by applicant]
Behlke, Chemical modification of siRNAs for in vivo use, Oligonucleotides. 18:305-319 (2008). [cited by applicant]
Belfort et al., Homing endonucleases: from genetic anomalies to programmable genomic clippers Methods Mal. Biol. 1123:1-26 (2014). [cited by applicant]
Boch et al., Breaking the code of DNA binding specificity of TAL-type III effectors, Science. 326:1509-12 (2009). [cited by applicant]
Boissel et al., “megaTALs” a rare-cleaving nuclease architecture for therapeutic genome engineering, Nucleic Acids Research, 2014, vol. 42, No. 4 (pp. 2591-2601). [cited by applicant]
Boissel et al., Assembly and characterization of megaTALs for hyperspecific genome engineering applications, Methods Mal. Biol. 1239:171-96 (2015). [cited by applicant]
Bolduc et al., “Recessive Mutations in the Putative Calcium-Activated Chloride Channel Anoctamin 5 Cause Proximal LGMD2L and Distal MMD3 Muscular Dystrophies”, The American Journal of Human Genetics, 86, Feb. 12, 2010, … [cited by applicant]
Bouquet et al., Miyoshi-like distal myopathy with mutations in anoctamin 5 gene, Rev. Neural. (Paris), 168(2):135-41 (Feb. 2012). [cited by applicant]
Bramsen et al., Development of therapeutic-grade small interfering RNAs by chemical engineering, Front. Genet. 20:154 (2012). [cited by applicant]
Carter et al., “Adeno-associated virus vectors,” Current Opinions in Biotechnology, 1992, vol. 3, Issue 5, pp. 533-539. [cited by applicant]
Ceccadi et al., Homologous recombination-deficient tumors are hyper-dependent on POLQ mediated repair, Nature. 518:258-262 (2015). [cited by applicant]
Cekaite et al., Gene expression analysis in blood cells in response to unmodified and 2′-modified siRNAs reveals TLR-dependent and independent effects, J. Mal. Biol. 365:90-108 (2007). [cited by applicant]
Centner et al., Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain, J. Mal. Biol. 306:717-26 (2001). [cited by applicant]
Cermak et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting,” Nucleic Acids Research, 2011, (pp. 1-11). [cited by applicant]
Cermak et al., Efficient design and assembly of custom TALENs using the Golden Gate platform, Methods Mal. Biol. 1239:133-59 (2015). [cited by applicant]
Ceyhan-Birsoy et al., Recessive truncating titin gene, TTN, mutations presenting as centronuclea1 myopathy, Neuroloov. 81:1205-14 (2013). [cited by applicant]
Chandrasekharan et al., Genetic defects in muscular dystrophy, Methods Enzymol. 479:291-322 (2010). [cited by applicant]
Chauveau et al., A rising titan: TTN review and mutation update, Human Mutation. 35:1046-59 (2014). [cited by applicant]
Chernolovskaya et al., Chemical modification of siRNA, Curr. Opin. Mal. Ther. 12:158-67 (2010). [cited by applicant]
Chiorini et al., Cloning and characterization of adeno-associated virus type 5, J. Viral., 73(2):1309-19 (Feb. 1999). [cited by applicant]
Chiorini et al., Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles, J. Viral., 71 (9):6823-33 (Sep. 1997). [cited by applicant]
Cho et al., DNA repair: Familiar ends with alternative endings, Nature. 518:174-6 (2015). [cited by applicant]
Cox et al., “Therapeutic genome editing: prospects and challenges,” Nature Medicine, Feb. 21, 2015, vol. 2 (pp. 121-131). [cited by applicant]
D'Amario et al., Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies, Gire. Res. 108:857-61 (2011). [cited by applicant]
Database Genbank [online], Accession No. AJ277892.2, Nov. 14, 2006 issue. [cited by applicant]
Daya et al., “Gene Therapy Using Adeno-Associated Virus Vectors,” Clinical Microbiology Reviews, Oct. 2008, vol. 21, No. 4 (pp. 583-593). [cited by applicant]
Deleavey et al., Chemical modification of siRNA, Curr. Protoc. Nucleic Acid Chem. Chapter 16: Unit 16.3 (2009). [cited by applicant]
Doench et al., “Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9”, Nature Biotechnology, Feb. 2016, vol. 34, No. 2 (pp. 184-191). [cited by applicant]
Dreier et al., “Development of Zinc Finger Domains for Recognition of the 5′-ANN-3′ Family of DNA Sequences and Their Use in the Construction of Artificial Transcription Factors,” The Journal of Biological Chemistry, Au… [cited by applicant]
Dreier et al., Insights into the molecular recognition of the 5′-GNN-3′ family of DNA sequences by zinc finger domains, J. Mal. Biol. 303:489-502 (2000). [cited by applicant]
Dreier, B. et al, “Development of zinc finger domains for recognition of the 5′-CNN-3′ family DNA sequence and their use in the construction of artificial transcription factors”, The Journal of Biological Chemistry, vol… [cited by applicant]
Fanin et al., Gender difference in limb-girdle muscular dystrophy: a muscle fiber morphometric study in 101 patients, Clin. Neuropathology, 33:179-801 (2014). [cited by applicant]
Fonfara et al., “Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems”, Nucleic Acids Research, vol. 42, No. 4, Nov. 22, 2013, pp. 2377-2590 (14 pages… [cited by applicant]
Forbes et al., “Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy”, Radiology, 269:198-207 (2013). [cited by applicant]
Foye, Whole Genome Sequencing Solved Our Family's Genetic Mystery: Titin, Narrat. Inq. Bioeth 5:206-8 (2015). [cited by applicant]
Fucini et al., Adenosine modification may be preferred for reducing siRNA immune stimulation, Nucleic Acid Ther. 22:205-210 (2012). [cited by applicant]
Gaglione et al., Recent progress in chemically modified siRNAs, Mini. Rev. Med. Chem. 10:578-9t (2010). [cited by applicant]
Gao et al., A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse, Gire. Res. 107:1445-53 (2010). [cited by applicant]
Gao et al., A novel and efficient model of coronary artery ligation in the mouse, Methods Mal. Bic 1037:299-311 (2013). [cited by applicant]
Gao et al., Adeno-associated viruses undergo substantial evolution in primates during natural infections, Proc. Natl. Acad. Sci. U.S.A., 2003, vol. 100, pp. 6081-6086. [cited by applicant]
Gautel et al., The central Z-disk region of titin is assembled from a novel repeat in variable copy numbers, Journal of Cell Science. 109:2747-2754 (1996). [cited by applicant]
Gebeyehu, et al., “Novel biotinylated nucleotide—analogs for labeling and colorimetric detection of DNA,” Nucleic Acids Research, vol. 15, No. 11, (Jun. 11, 1987), p. 4513-4534. [cited by applicant]
GenBank Accession No. AF028704.1, Adena-associated virus 6, complete genome, Jan. 12, 1998. [cited by applicant]
GenBank Accession No. AF028705.1, Adeno-associated virus 3B, complete genome, Jan. 12, 1998. [cited by applicant]
GenBank Accession No. AX753250.1, Sequence 5 from Patent EP1310571, Jun. 23, 2003. [cited by applicant]
GenBank Accession No. AY631965.1, Adena-associated virus 10 nonstructural protein and caps protein genes, complete eds, Nov. 30, 2004. [cited by applicant]
GenBank Accession No. AY631966.1, Adena-associated virus 11 nonstructural protein and caps protein genes, complete eds, Nov. 30, 2004. [cited by applicant]
GenBank Accession No. DO813647.1, Adena-associated virus 12 Rep78 and VP1 genes, complete eds, Feb. 20, 2008. [cited by applicant]
GenBank Accession No. EU285562.1, Adena-associated virus 13 nonstructural protein and capsid protein genes, complete eds, Sep. 23, 2008. [cited by applicant]
GenBank Accession No. NC_001401.2, Adeno-associated virus—2, complete genome, Aug. 13, 2018. [cited by applicant]
GenBank Accession No. NC_006152.1, Adeno-associated virus 5, complete genome, Aug. 13, 2018. [cited by applicant]
GenBank Accession No. NC_006260.1, Adeno-associated virus—7, complete genome, Aug. 13, 2018. [cited by applicant]
GenBank Accession No. NC_006261.1, Adeno-associated virus—8, complete genome, Aug. 13, 2018. [cited by applicant]
Genbank Accession No. J01901, Adeno-associated virus 2, complete genome, Apr. 27, 1993. [cited by applicant]
GenBank Accession No. U89790.1, Adeno-associated virus 4, complete genome, Aug. 21, 2017. [cited by applicant]
GenBank Registered No. NG_011618, [cited by applicant]
Genbank Synthetic construct Homo sapiens clone Image: 100069183, MGC: 199194 anoctamin 5 (ANO5) mRNA, encodes complete protein GenBank: BC172489.1, (2009). [cited by applicant]
Georganopoulou et al., “A Journey with LGMD: From Protein Abnormalities to Patient Impact”, The Protein Journal, Kluwer Academic/Plenum Publishers, Dordrecht, NL, vol. 40, No. 4, Jun. 10, 2021, pp. 466-488. [cited by applicant]
Gerull et al., Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy, J. Mal. Med. (Berl). 84:478-83 (2006). [cited by applicant]
Gerull et al., Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy, Nat. Genet. 30:201-4 (2002). [cited by applicant]
Goeddel, “Gene Expression Technology: Methods in Enzymology,” Academic Press, vol. 185, Jun. 11, 1990, pp. 3-7. [cited by applicant]
Gombash et al., Adeno-Associated Viral Vector Delivery to the Enteric Nervous System: A Review, Postdoc J., 2015, vol. 3, Issue 8, pp. 1-12. [cited by applicant]
Govoni et al., “Ongoing therapeutics trials and outcome measures for Duchenne muscular dystrophy”, Cell Mol. Life Sci., 70:4585-602 (2013). [cited by applicant]
Gramlich et al., “Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy,” EMBO Molecular Medicine, 7(5): 562-76 (2015). [cited by applicant]
Gramlich et al., “Stress-induced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease”, J. Mal. Cell Cadiol. 47:352-8 (2009). [cited by applicant]
Granzier et al., “Deleting titin's I-band/A-band junction reveals critical roles for titin in biomechanica sensing and cardiac function”, Proc. Natl. Acad. Sci. USA. 111:14589-94 (2014). [cited by applicant]
Griffin et al., Defective Membrane Fusion and Repair in Anoctamin5-Deficient Muscular Dystrophy, Human Molecular Genetics, vol. 25, No. 10, pp. 1900-1911 (Feb. 23, 2016). [cited by applicant]
Griffin et al., “Dose-Escalation of Systemically Delivered Adeno-Associated Virus-Mediated alpha-Sarcoglycan in a Mouse Model With Limb-Girdle Muscular Dystrophy Type 2D,” Presented at the 2019 Muscular Dystrophy Associ… [cited by applicant]
Griffin et al., “Systemic Dose Escalation Study of Alpha-Sarcoglycan Provides Functional Improvement in SGCA (I-) Mouse Model of LGMD2D,” Molecular Therapy, vol. 26, No. 5S1, May 2018, p. 166. [cited by applicant]
Grose et al., “Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer”, PLoS One, Jun. 2012, vol. 7, Issue 6, e39233. [cited by applicant]
Guilinger et al., “Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification,” Nature Biotechnology, vol. 32, No. 6, Jun. 2014 (pp. 577-582). [cited by applicant]
Gutschner et al., “Genome engineering—Matching supply with demand,” Cell Cycle, 15(11): 1395-96 2016. [cited by applicant]
Hafez et al., “Homing endonucleases: DNA scissors on a mission”, Genome. 55:553-69 (2012). [cited by applicant]
Hagan, “When are mice considered old?” The Jackson Laboratory, https://www.jax.org/news-and-insights/jax-blog/2017/november/when-are-mice-considered-old# Nov. 7, 2017 (8 pages). [cited by applicant]
Hakim et al., Monitoring murine skeletal muscle function for muscle gene therapy, Methods Mal. Biol., 2011, vol. 709, pp. 75-89. [cited by applicant]
Handschin et al., Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism, Endocrine reviews, 27:728-735 (2002). [cited by applicant]
Herman et al., “Truncations of titin causing dilated cardiomyopathy”, N. Engl. J. Med. 366:619-28, 2012. [cited by applicant]
Hicks et al., A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy, Brain, 134 (Pt. 1):171-82 (Jan. 2011). [cited by applicant]
Horii et al., Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering, Sci Rep. 4:4513 (2014). [cited by applicant]
International Application No. PCT/US12/66265, International Search Report and Written Opinion, mailed Mar. 28, 2013. [cited by applicant]
International Application No. PCT/US19/39893, International Preliminary Report on Patentability, mailed Jan. 7, 2021. [cited by applicant]
International Application No. PCT/US19/39893, International Search Report and Written Opinion, mailed Sep. 25, 2019. [cited by applicant]
International Application No. PCT/US20/47339, International Preliminary Report on Patentability, mailed Mar. 3, 2022. [cited by applicant]
International Application No. PCT/US2016/061703, International Preliminary Report on Patentability, mailed May 15, 2018. [cited by applicant]
International Preliminary Report on Patentability for Appl. Ser. No. PCT/US2019/039893 dated Dec. 29, 2020 (7 pages). [cited by applicant]
International Preliminary Report on Patentability for Appl. Ser. No. PCT/US2016/062052 dated May 22, 2018. [cited by applicant]
International Preliminary Report on Patentability on PCT Appl. No. PCT/US2012/066265 dated May 27, 2014 (9 pages). [cited by applicant]
International Search Report and Written Opinion for Appl. Ser. No. PCT/US2016/062052 dated Feb. 7, 2017 (5 pages). [cited by applicant]
International Search Report and Written Opinion for Appl. Ser. No. PCTUS2016/061703 dated Feb. 2, 2017 (13 pages). [cited by applicant]
International Search Report and Written Opinion on PCT Appl. No. PCT/US2020/047339 dated Dec. 10, 2020 (12 pages). [cited by applicant]
Itoh-Satoh et al., Titan mutations as the molecular basis for dilated cardiomyopathy, Biochem. Biophys. Res. Commun. 291:385-93 (2002). [cited by applicant]
Jaber et al., Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insight, Circ. Heart Fail. 1:192-9 (2008). [cited by applicant]
Jinek et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science, Aug. 17, 2012, 337(6096):816-821. [cited by applicant]
John Hopkins Medicine, “Types of Muscular Dystrophy and Neuromuscular diseases,” 2023, 6 pages. [cited by applicant]
Judge et al., “Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo”, Mol. Ther. 13:494-505 (2006). [cited by applicant]
Justison et al., Percutaneous assisted venous return isolated limb perfusion, J. Extra Corpor. Technol., 2009, vol. 41, Issue 4, pp. 231-234. [cited by applicant]
Kajigaya et al., Self-assembled B19 parvovirus caps ids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions, Proc. Natl. Acad. Sci. USA, 88(11):4646- 50 (Jun. 1991). [cited by applicant]
Kariko et al., “Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA,” Immunity, Aug. 2005, vol. 23 (pp. 165-175). [cited by applicant]
Kennell, “Principles and Practices of Nucleic Acid Hybridization,” Progress in Nucleic Acid Research and Molecular Biology, Academic Press, vol. 11, 1971, (pp. 259-301). [cited by applicant]
Kent et al., “Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase theta”, Nat. Struct. Mol. Biol. 22:230-237 (2015). [cited by applicant]
Kirnbauer et al., Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization, Virology, 219(1 ):37-44 (May 1996). [cited by applicant]
Kleinstiver et al., The I-Tevl nuclease and linker domains contribute to the specificity of monomerh TALENs, G3 (Bethesda). 4:1155-65 (2014). [cited by applicant]
Kole et al., “RNA therapeutics: beyond RNA interference and antisense oligonucleotides”, Nat Rev Drug Discov. Jan. 20, 2012;11(2):125-40. doi: 10.1038/nrd3625. [cited by applicant]
Kolmerer et al., “Genomic organization of M line titin and its tissue-specific expression in two distinct isoforms”, J. Mol. Biol. 256:556-63 (1996). [cited by applicant]
Kormann et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice,” Nature Biotechnology, Feb. 2011, vol. 29, No. 2 (pp. 154-157). [cited by applicant]
Kornberg et al., “The early history of DNA polymerase: a commentary by Arthur Kornberg”, Biochimica et Biophysica Acta. 1000:53-56 (1989). [cited by applicant]
Kotin et al., “Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines,” Human Gene Therapy, 28(4):Abstract Only, (Apr. 1, 2017). [cited by applicant]
Kramerova et al., “Null mutation of calpain 3 {p94) in mice causes abnormal sarcomere formation in vivo and in vitro”, Hum. Mol. Genet., 13(13):1373-1388 (2004). [cited by applicant]
Kramerova et al., Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A calpainopathy, Hum. Mol. Genet., 25(11):2194-2207 (2016). [cited by applicant]
Labeit et al., “Titins: giant proteins in charge of muscle ultrastructure and elasticity”, Science. 270:293-6 (1995). [cited by applicant]
Lewinter et al., Cardiac titin and heart disease, J. Cardiovasc. Pharmacol. 63:207-12 (2014). [cited by applicant]
Lewinter, “Titin isoforms in heart failure: are there benefits to supersizing”, Circulation. 110:109-11 2004. [cited by applicant]
Li et al., “Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes,” Nucleic Acids Research, 2011, vol. 39, No. 14 (pp. 6315-6325). [cited by applicant]
Li et al., Electrical impedance myography for the in vivo and ex vivo assessment of muscular dystrophy (mdx) mouse muscle, Muscle Nerve, 49(6):829-35 (Jun. 2014). [cited by applicant]
Li et al., Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice, PLoS One, 8(6):e65976 (Jun. 2013). [cited by applicant]
Li et al., Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models, Basic Res. Cardiol. 106:849-64 (2011). [cited by applicant]
Lin et al., Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres, Nature, 418:797-801 (2002). [cited by applicant]
Liu et al., “Validated Zinc Finger Protein Designs for All 16 GNN DNA Triplet Targets,” The Journal of Biological Chemistry, Feb. 8, 2002, vol. 277, No. 6 (pp. 3850-3856). [cited by applicant]